SR9011
Identifiers | |
---|---|
| |
CAS Number | 1379686-29-9 |
PubChem (CID) | 57394021 |
ChemSpider | 28487552 |
ChEMBL | CHEMBL1961797 |
Chemical and physical data | |
Formula | C23H31ClN4O3S |
Molar mass | 479.03524 g/mol |
3D model (Jmol) | Interactive image |
| |
|
SR9011 is a research drug that was developed by Professor Thomas Burris of Scripps as an agonist of Rev-ErbAα with a half-maximum inhibitory concentration (IC50) = 790 nM for Rev-Erbα and IC50 = 560 nM for Rev-ErbAβ.[1]
See also
References
- ↑ Solt LA; Wang Y; Banerjee S; Hughes T; Kojetin DJ; Lundasen T; Shin Y; Liu J; Cameron MD; Noel R; Yoo SH; Takahashi JS; Butler AA; Kamenecka TM; Burris TP (May 2012). "Regulation of circadian behaviour and metabolism by synthetic REV-ERB agonists". Nature. 485 (7396): 62–8. doi:10.1038/nature11030. PMC 3343186. PMID 22460951. Lay summary – Nature Magazine.
This article is issued from Wikipedia - version of the 6/5/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.